Matches in Nanopublications for { ?s ?p "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP177976.RA_uGcVrTdi0sKGaR7r1BcOkxhvmLWLUKRK7Fy45tb2dA130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP177976.RA_uGcVrTdi0sKGaR7r1BcOkxhvmLWLUKRK7Fy45tb2dA130_provenance.
- NP923903.RAdcdn_0VY56hLdU9-dAkxE2qzLPSJs94jSmbZJeR8m1o130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP923903.RAdcdn_0VY56hLdU9-dAkxE2qzLPSJs94jSmbZJeR8m1o130_provenance.
- NP430536.RAuHUGQYTJUAvKOynr0p_fEBChS1RyhyrQBhBVQSN8xd0130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430536.RAuHUGQYTJUAvKOynr0p_fEBChS1RyhyrQBhBVQSN8xd0130_provenance.
- NP459428.RApaU-oA4MLlFuiFM-3HFE9Ac3zll8aZuruXIgKpXK4Y4130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP459428.RApaU-oA4MLlFuiFM-3HFE9Ac3zll8aZuruXIgKpXK4Y4130_provenance.
- NP602810.RAZZHOZB26ics0Pe7wTabvIrWRqA2Vcnc5mUG77Br7EnU130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP602810.RAZZHOZB26ics0Pe7wTabvIrWRqA2Vcnc5mUG77Br7EnU130_provenance.
- NP608114.RATpDIgWddVHuaYRxmlzozj5pJ6cN7KcX6IWu7XcoEtLs130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP608114.RATpDIgWddVHuaYRxmlzozj5pJ6cN7KcX6IWu7XcoEtLs130_provenance.
- NP736336.RAZTobezkNrPtithCnQjQnAumEpk7dJm50g4xvalXrd2I130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP736336.RAZTobezkNrPtithCnQjQnAumEpk7dJm50g4xvalXrd2I130_provenance.
- NP420474.RAHFnSutvB-G2LhmZMsK1lwxF5eCf7GoU3UEZSRaQa_oc130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420474.RAHFnSutvB-G2LhmZMsK1lwxF5eCf7GoU3UEZSRaQa_oc130_provenance.
- NP789608.RASjEsQwz6RBLPrECBvM8_ZezHWxJlfiMpDbvLwhAC1Pc130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP789608.RASjEsQwz6RBLPrECBvM8_ZezHWxJlfiMpDbvLwhAC1Pc130_provenance.
- NP711666.RA3J-iJ5BXMh14QhvPaLV44UyQxE_3IYVk6uICE2jp7CU130_assertion description "[CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP711666.RA3J-iJ5BXMh14QhvPaLV44UyQxE_3IYVk6uICE2jp7CU130_provenance.